{
  "data": [
    {
      "id": "stat_6GFRH7RQ2VT2J7HH6HGVSK94SF",
      "url": "https://statorigin.org/stat/stat_6GFRH7RQ2VT2J7HH6HGVSK94SF",
      "indicator": {
        "slug": "chemically-synthesized-share-of-new-medicine-launches",
        "name": "Chemically synthesized share of new medicine launches",
        "definition": "Percentage of newly launched medicines containing chemically synthesized active substances."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "DE",
        "name": "Germany",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 57,
      "value_text": "57 Prozent",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "VFA",
        "org_short_name": "VFA",
        "org_url": "https://www.vfa.de",
        "org_tier": 2,
        "document_title": "Neue Medikamente in Deutschland: Innovationsbilanz 2025",
        "document_url": "https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025",
        "document_type": "press_release",
        "locator": "Herstellungsarten",
        "quote": "Wie schon 2024 enthält die Mehrheit (57 Prozent) der neuen Medikamente von 2025 chemisch synthetisierte Wirkstoffe.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "VFA. (2025). Neue Medikamente in Deutschland: Innovationsbilanz 2025. Retrieved September 17, 2026, from https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Via StatOrigin, https://statorigin.org/stat/stat_6GFRH7RQ2VT2J7HH6HGVSK94SF",
        "bibtex": "@misc{vfa2025chemicallysk94sf,\n  author       = {{VFA}},\n  title        = {Neue Medikamente in Deutschland: Innovationsbilanz 2025},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_6GFRH7RQ2VT2J7HH6HGVSK94SF},\n  note         = {Original source: https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_05HZG55CCY2YWAZFFKT8YKEZCZ",
      "url": "https://statorigin.org/stat/stat_05HZG55CCY2YWAZFFKT8YKEZCZ",
      "indicator": {
        "slug": "genetically-engineered-share-of-new-medicine-launches",
        "name": "Genetically engineered share of new medicine launches",
        "definition": "Percentage of newly launched medicines produced using genetic engineering."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "DE",
        "name": "Germany",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 41,
      "value_text": "41 Prozent",
      "unit": "percent",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "VFA",
        "org_short_name": "VFA",
        "org_url": "https://www.vfa.de",
        "org_tier": 2,
        "document_title": "Neue Medikamente in Deutschland: Innovationsbilanz 2025",
        "document_url": "https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025",
        "document_type": "press_release",
        "locator": "Herstellungsarten",
        "quote": "Weitere 41 Prozent der Medikamente werden gentechnisch hergestellt.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "VFA. (2025). Neue Medikamente in Deutschland: Innovationsbilanz 2025. Retrieved September 17, 2026, from https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Via StatOrigin, https://statorigin.org/stat/stat_05HZG55CCY2YWAZFFKT8YKEZCZ",
        "bibtex": "@misc{vfa2025geneticallyykezcz,\n  author       = {{VFA}},\n  title        = {Neue Medikamente in Deutschland: Innovationsbilanz 2025},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_05HZG55CCY2YWAZFFKT8YKEZCZ},\n  note         = {Original source: https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_HCJGZDM0RCZETH17164MGV03WD",
      "url": "https://statorigin.org/stat/stat_HCJGZDM0RCZETH17164MGV03WD",
      "indicator": {
        "slug": "label-extensions-for-approved-medicines",
        "name": "Label extensions for approved medicines",
        "definition": "Number of authorization extensions expanding an approved medicine's therapeutic indications to additional diseases or patient populations."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "DE",
        "name": "Germany",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 20,
      "value_text": "mindestens 20",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "VFA",
        "org_short_name": "VFA",
        "org_url": "https://www.vfa.de",
        "org_tier": 2,
        "document_title": "Neue Medikamente in Deutschland: Innovationsbilanz 2025",
        "document_url": "https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025",
        "document_type": "press_release",
        "locator": "Innovationsbilanz 2025",
        "quote": "Hinzu kamen mindestens 20 Zulassungserweiterungen, also Erweiterungen des Anwendungsgebiets eines Medikaments auf zusätzliche Krankheiten oder Altersgruppen.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "VFA. (2025). Neue Medikamente in Deutschland: Innovationsbilanz 2025. Retrieved September 17, 2026, from https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Via StatOrigin, https://statorigin.org/stat/stat_HCJGZDM0RCZETH17164MGV03WD",
        "bibtex": "@misc{vfa2025labelgv03wd,\n  author       = {{VFA}},\n  title        = {Neue Medikamente in Deutschland: Innovationsbilanz 2025},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_HCJGZDM0RCZETH17164MGV03WD},\n  note         = {Original source: https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_MFSFNNEE1TKBS57HHBHWMMY3HT",
      "url": "https://statorigin.org/stat/stat_MFSFNNEE1TKBS57HHBHWMMY3HT",
      "indicator": {
        "slug": "new-medicines-launched-with-orphan-drug-designation",
        "name": "New medicines launched with orphan drug designation",
        "definition": "Number of newly launched medicines that have received official orphan drug designation from regulatory authorities."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "DE",
        "name": "Germany",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 14,
      "value_text": "14",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "VFA",
        "org_short_name": "VFA",
        "org_url": "https://www.vfa.de",
        "org_tier": 2,
        "document_title": "Neue Medikamente in Deutschland: Innovationsbilanz 2025",
        "document_url": "https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025",
        "document_type": "press_release",
        "locator": "Medikamente gegen seltene Erkrankungen",
        "quote": "14 der Medikamente erhielten auf Antrag ihrer Hersteller von der EU den Orphan Drug-Status zuerkannt; er attestiert ihnen, zumindest für einen Teil der Erkrankten den bisherigen Behandlungsmöglichkeiten überlegen zu sein.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "VFA. (2025). Neue Medikamente in Deutschland: Innovationsbilanz 2025. Retrieved September 17, 2026, from https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Via StatOrigin, https://statorigin.org/stat/stat_MFSFNNEE1TKBS57HHBHWMMY3HT",
        "bibtex": "@misc{vfa2025medicinesmmy3ht,\n  author       = {{VFA}},\n  title        = {Neue Medikamente in Deutschland: Innovationsbilanz 2025},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_MFSFNNEE1TKBS57HHBHWMMY3HT},\n  note         = {Original source: https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_MR654CEM46NRJD4PSHSWXH43S3",
      "url": "https://statorigin.org/stat/stat_MR654CEM46NRJD4PSHSWXH43S3",
      "indicator": {
        "slug": "new-rare-disease-drug-launches",
        "name": "New rare disease drug launches",
        "definition": "Number of newly launched medicines indicated for the treatment of rare diseases."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "DE",
        "name": "Germany",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 25,
      "value_text": "25",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "VFA",
        "org_short_name": "VFA",
        "org_url": "https://www.vfa.de",
        "org_tier": 2,
        "document_title": "Neue Medikamente in Deutschland: Innovationsbilanz 2025",
        "document_url": "https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025",
        "document_type": "press_release",
        "locator": "Medikamente gegen seltene Erkrankungen",
        "quote": "Rund zwei Drittel (25 Medikamente) der neu eingeführten Medikamente haben eine seltene Erkrankung als Anwendungsgebiet ‒ es leiden daran also nicht mehr als fünf von 10.000 EU-Bürger:innen.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "VFA. (2025). Neue Medikamente in Deutschland: Innovationsbilanz 2025. Retrieved September 17, 2026, from https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Via StatOrigin, https://statorigin.org/stat/stat_MR654CEM46NRJD4PSHSWXH43S3",
        "bibtex": "@misc{vfa2025rarexh43s3,\n  author       = {{VFA}},\n  title        = {Neue Medikamente in Deutschland: Innovationsbilanz 2025},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_MR654CEM46NRJD4PSHSWXH43S3},\n  note         = {Original source: https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    },
    {
      "id": "stat_4KBRYJZ86RHCXSACZ47BBQX1KD",
      "url": "https://statorigin.org/stat/stat_4KBRYJZ86RHCXSACZ47BBQX1KD",
      "indicator": {
        "slug": "novel-active-substance-launches",
        "name": "Novel active substance launches",
        "definition": "Total number of novel active substances launched."
      },
      "industry": [
        {
          "slug": "pharmaceuticals",
          "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
          "isic": "C21",
          "is_primary": true
        }
      ],
      "region": {
        "code": "DE",
        "name": "Germany",
        "type": "country"
      },
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "type": "year"
      },
      "value": 37,
      "value_text": "37",
      "unit": "count",
      "currency": null,
      "scale": "1",
      "value_type": "actual",
      "source": {
        "org": "VFA",
        "org_short_name": "VFA",
        "org_url": "https://www.vfa.de",
        "org_tier": 2,
        "document_title": "Neue Medikamente in Deutschland: Innovationsbilanz 2025",
        "document_url": "https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025",
        "document_type": "press_release",
        "locator": "Innovationsbilanz 2025",
        "quote": "Pharmaunternehmen in Deutschland haben 2025 insgesamt 37 Medikamente mit neuen Wirkstoffen auf den Markt gebracht.",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok"
      },
      "verification": "verified",
      "verified_by": "seed:auto-extract-v1",
      "verified_at": "2026-09-17T07:16:01.811Z",
      "confidence": 0.9,
      "is_secondhand": false,
      "supersedes": null,
      "superseded_by": null,
      "is_current": true,
      "citation": {
        "apa": "VFA. (2025). Neue Medikamente in Deutschland: Innovationsbilanz 2025. Retrieved September 17, 2026, from https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Via StatOrigin, https://statorigin.org/stat/stat_4KBRYJZ86RHCXSACZ47BBQX1KD",
        "bibtex": "@misc{vfa2025novelbqx1kd,\n  author       = {{VFA}},\n  title        = {Neue Medikamente in Deutschland: Innovationsbilanz 2025},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_4KBRYJZ86RHCXSACZ47BBQX1KD},\n  note         = {Original source: https://www.vfa.de/de/forschung-entwicklung/meilensteine-und-neueinfuehrungen/innovationsbilanz-2025. Accessed September 17, 2026.}\n}"
      },
      "updated_at": "2026-09-17T07:16:01.811Z"
    }
  ],
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 6,
    "limit": 50,
    "next_cursor": null
  }
}